Multiple System Atrophy
Multiple system atrophy (MSA) is a progressive neurodegenerative disorder characterized by a combination of symptoms that affect both the autonomic nervous system and movement.The etiology of MSA is unknown and majority of the cases are sporadic. A distinguishing feature of MSA is the accumulation of alpha-synuclein. These deposits of alpha-synuclein particularly occur in oligodendroglia, a type of cell that makes myelin (a coating on nerve cells that lets them conduct electrical signals rapidly).
&nbsp;
Multiple System Atrophy Epidemiology Segmentation in the 7MM
&nbsp;
<ul>
<li class="ql-align-justify">Diagnosed Prevalent Cases</li>
<li class="ql-align-justify">Gender-specific Diagnosed Prevalent Cases</li>
<li class="ql-align-justify">Age-specific Diagnosed Prevalent Cases</li>
<li class="ql-align-justify">Type-specific Diagnosed Prevalent Cases</li>
</ul>
&nbsp;
<a style="color: black;" href="https://www.delveinsight.com/report-store/multiple-system-atrophy-msa-epidemiology-forecast" target="_blank" rel="noopener noreferrer">Multiple System Atrophy Epidemiological Insights Observed in the 7MM</a> (2021)
The total number of incident cases of Multiple System Atrophy observed in the 7MM was observed to be 36K in the year 2021.
&nbsp;
<a style="color: black;" href="https://www.delveinsight.com/report-store/multiple-system-atrophy-msa-market" target="_blank" rel="noopener noreferrer">Multiple System Atrophy Market Insight</a>
The market size of Multiple System Atrophy in the 7MM was found to be approximately USD 125 billion in 2022.
&nbsp;
Multiple System Atrophy Market Strengths
Increased understanding of neuropathological aspects underlying MSA has strengthened the disease understanding in recent years.
&nbsp;
Multiple System Atrophy Market Opportunities
Research studies with effective MoAs to treat MSA neuroprotective confer myriads of great opportunities to the key pharma players.
&nbsp;
Multiple System Atrophy Emerging Drugs and Key Players&nbsp;
&nbsp;
<ul>
<li class="ql-align-justify">Lu AF82422: H Lundbeck A/S</li>
<li class="ql-align-justify">Ampreloxetine (TD-9855): Theravance Biopharma</li>
<li class="ql-align-justify">AAV2-GDNF Gene Therapy: Brain Neurotherapy Bio, Inc.</li>
<li class="ql-align-justify">ION464: Ionis Pharmaceuticals, Inc</li>
<li class="ql-align-justify">ATH434: Alterity Therapeutics</li>
</ul>
&nbsp;

Multiple System Atrophy Market

Multiple System Atrophy Market Infographics

Multiple System Atrophy Symptoms, Treatment, epidemiology, companies, drugs, infographic is a short guide to understand the problem and market landscape